Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Firdapse for Treatment of Rare Autoimmune Disorder

By Catalyst Pharmaceuticals, Inc. | November 30, 2018

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, has received U.S. Food and Drug Administration (FDA) approval for Firdapse (amifampridine) 10 mg tablets to treat adults with Lambert-Eaton myasthenic syndrome (LEMS).

Firdapse is expected to be commercially available early in the first quarter of 2019.

LEMS is a rare autoimmune disease that affects approximately one in 100,000 people in the United States. The most common symptoms of LEMS are proximal muscle weakness and fatigue. Symptoms can be life threatening when the weakness involves respiratory muscles. Approximately 50 percent of LEMS patients have an underlying malignancy, typically small cell lung cancer.

The submission of the Firdapse NDA came following positive results from two Phase 3 studies where patients treated with Firdapse experienced rapid, significant, and sustained improvements in muscle function, and reduced weakness and fatigability compared to patients receiving placebo. The drug  previously had received Orphan Drug designation and Breakthrough Therapy designation, as well as Priority Review from the FDA. Firdapse is the first and only approved drug in Europe for treatment of LEMS.

Gary Ingenito, M.D., Ph.D., chief medical officer at Catalyst, said the company plans to continue to work with the FDA to evaluate other potential indications for Firdapse. 

(Source: Catalyst Pharmaceuticals, Inc.)

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards